Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy for High-risk Diffuse Large B-cell Lymphoma

NCT03458546 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at San Antonio as lead sponsor.

NCT NCT03458546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03458546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy for High-risk Diffuse Large B-cell Lymphoma
Lead sponsor
The University of Texas Health Science Center at San Antonio
Phase
Phase 1
Overall status
Completed
Start date
May 21, 2018
Completion date
January 16, 2024
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell